Neurodegeneration in Parkinson's disease: Interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and sirtuins

Molecular Neurobiology

Volumn 49, Issue 2, 2014, Pages 771-783

  Anderson, George ^a   Maes, Michael ^b  

^a CRC   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

cAMP; Depression; Immuno inflammation; Neurodegeneration; O NS; Parkinson's disease; Somatization; TRYCATs

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; ANTIOXIDANT; AROMATIC HYDROCARBON RECEPTOR; ASCORBIC ACID; CATALASE; CYCLIC AMP; DNA; DOPAMINE; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; GLUTAMIC ACID; GLUTATHIONE; INFLAMMASOME; KYNURENIC ACID; NICOTINAMIDE ADENINE DINUCLEOTIDE; POLY(ADENOSINE DIPHOSPHATE RIBOSE); REACTIVE OXYGEN METABOLITE; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 5; SUBSTANCE P; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR CLOCK; TRYPTOPHAN; TYROSINE 3 MONOOXYGENASE; UNINDEXED DRUG;

AGING; APOPTOSIS; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN MITOCHONDRION; CENTRAL NERVOUS SYSTEM; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA DAMAGE; DNA REPAIR; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; EXCITOTOXICITY; GENE EXPRESSION; HUMAN; INFLAMMATION; LIPID PEROXIDATION; MAST CELL DEGRANULATION; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SOMATIZATION; SUBSTANTIA NIGRA; TRYPTOPHAN METABOLISM; ANIMAL; BRAIN; METABOLISM; MITOCHONDRION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; DEPRESSION; HUMANS; LIPID PEROXIDATION; MITOCHONDRIA; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; SIRTUINS; TRYPTOPHAN;

EID: 84896401100     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8554-z     Document Type: Review

References (147)

1. Wang A, Costello S, Cockburn M, Zhang X, Bronstein J, Ritz B (2011) Parkinson's disease risk from ambient exposure to pesticides. Eur J Epidemiol 26:547-555
2. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 26(Suppl 1):S1-S58
3. Dardiotis E, Xiromerisiou G, Hadjichristodoulou C, Tsatsakis AM, Wilks MF, Hadjigeorgiou GM (2013) The interplay between environmental and genetic factors in Parkinson's disease susceptibility: the evidence for pesticides. Toxicology 307:17-23
4. Anderson G, Maes M (2013) TRYCAT pathways link peripheral inflammation, nicotine, somatization and depression in the etiology and course of Parkinson's disease. CNS Neurol Dis Drug Targets (in press)
5. Liebau C, Baltzer AW, Schmidt S, Roesel C, Karreman C, Prisack JB, Bojar H, Merk H (2002) Interleukin-12 and interleukin-18 induce indoleamine 2,3-dioxygenase (IDO) activity in human osteosarcoma cell lines independently from interferon-gamma. Anticancer Res 22(2A):931-936 (Pubitemid 34475252)
6. Thomas SR, Salahifar H, Mashima R, Hunt NH, Richardson DR, Stocker R (2001) Antioxidants inhibit indoleamine 2,3-dioxygenase in IFN-gamma-activated human macrophages: posttranslational regulation by pyrrolidine dithiocarbamate. J Immunol 166:6332-6340 (Pubitemid 32440766)
7. Ren S, Correia MA (2000) Heme: a regulator of rat hepatic tryptophan 2,3-dioxygenase. Arch Biochem Biophys 377(1):195-203 (Pubitemid 30257305)
8. Luchowska E, Kloc R, Olajossy B, Wnuk S, Wielosz M, Owe-Larsson B, Urbanska EM (2009) Beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signalling. Prog Neuropsychopharmacol Biol Psychiatry 33(3):519-529
9. Guillemin GJ, Smythe G, Takikawa O, Brew BJ (2005) Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia 49(1):15-23 (Pubitemid 40023649)
10. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012) Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 27(6):716-719
11. Videnovic A, Golombek D (2013) Circadian and sleep disorders in Parkinson's disease. Exp Neurol 243:45-56
12. Bugalho P, da Silva JA, Cargaleiro I, Serra M, Neto B (2012) Psychiatric symptoms screening in the early stages of Parkinson's disease. J Neurol 259(1):124-131
13. Maes M, Rief W (2012) Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 196:243-249
14. Anderson G, Maes M, Berk M (2012) Biological underpinnings of the commonalities in depression, somatization, and chronic fatigue syndrome. Med Hypotheses 78:752-756
15. Hartai Z, Klivenyi P, Janaky T, Penke B, Dux L, Vecsei L (2005) Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease. J Neurol Sci 239(1):31-35 (Pubitemid 41617412)
16. Knyihár-Csillik E, Chadaide Z, Mihály A, Krisztin-Péva B, Fenyo R, Vécsei L (2006) Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra. Acta Neuropathol 112(2):127-137
17. Silva-Adaya D, Pérez-De La Cruz V, Villeda-Hernández J, Carrillo-Mora P, González-Herrera IG, García E, Colín-Barenque L, Pedraza-Chaverrí J, Santamaría A (2011) Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33(2):303-312
18. Schuck PF, Tonin A, da Costa Ferreira G, Viegas CM, Latini A, Duval Wannmacher CM, de Souza Wyse AT, Dutra-Filho CS, Wajner M (2007) Kynurenines impair energy metabolism in rat cerebral cortex. Cell Mol Neurobiol 27(1):147-160 (Pubitemid 46169900)
19. Leipnitz G, Schumacher C, Scussiato K, Dalcin KB, Wannmacher CM, Wyse AT, Dutra-Filho CS, Wajner M, Latini A (2005) Quinolinic acid reduces the antioxidant defenses in cerebral cortex of young rats. Int J Dev Neurosci 23(8):695-701 (Pubitemid 41674508)
20. Leipnitz G, Schumacher C, Dalcin KB, Scussiato K, Solano A, Funchal C, Dutra-Filho CS, Wyse AT, Wannmacher CM, Latini A, Wajner M (2007) In vitro evidence for an antioxidant role of 3-hydroxykynurenine and 3-hydroxyanthranilic acid in the brain. Neurochem Int 50(1):83-94 (Pubitemid 44911063)
21. Zunszain PA, Anacker C, Cattaneo A, Choudhury S, Musaelyan K, Myint AM, Thuret S, Price J, Pariante CM (2012) Interleukin-1β: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37(4):939-949
22. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR (2010) Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behav Brain Res 210(1):84-91
23. Laugeray A, Launay JM, Callebert J, Surget A, Belzung C, Barone PR (2011) Evidence for a key role of the peripheral kynurenine pathway in the modulation of anxiety- and depression-like behaviours in mice: focus on individual differences. Pharmacol Biochem Behav 98:161-168
24. Maes M, Bosmans E, Scharpé S, D'Hondt P, Desnyder R (1995) Plasma soluble interleukin-2-receptor in depression: relationships to plasma neopterin and serum IL-2 concentrations and HPA-axis activity. Eur Psychiatry 10(8):397-403 (Pubitemid 26015268)
25. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E (2007) The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett 28(6):826-831
26. Devos D, Lebouvier T, Lardeux B, Biraud M, Rouaud T, Pouclet H, Coron E, Bruley des Varannes S, Naveilhan P, Nguyen JM, Neunlist M, Derkinderen P (2012) Colonic inflammation in Parkinson's disease. Neurobiol Dis 50C:42-48
27. Hernández-Romero MC, Delgado-Cortés MJ, Sarmiento M, de Pablos RM, Espinosa-Oliva AM, Argüelles S, Bández MJ, Villarán RF, Mauriño R, Santiago M, Venero JL, Herrera AJ, Cano J, Machado A (2012) Peripheral inflammation increases the deleterious effect of CNS inflammation on the nigrostriatal dopaminergic system. Neurotoxicology 33(3):347-360
28. Widner B, Leblhuber F, Fuchs D (2002) Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm 109(2):181-189 (Pubitemid 34185664)
29. Lewitt PA (2012) Norepinephrine: the next therapeutics frontier for Parkinson's disease. Transl Neurodegener 1(1):4
30. Bekar LK, Wei HS, Nedergaard M (2012) The locus coeruleus-norepinephrine network optimizes coupling of cerebral blood volume with oxygen demand. J Cereb Blood Flow Metab 32(12):2135-2145
31. Del Tredici K, Braak H (2013) Dysfunction of the locus coeruleus-norepinephrine system and related circuitry in Parkinson's disease-related dementia. J Neurol Neurosurg Psychiatry 84(7):774-783
32. Muñoz P, Huenchuguala S, Paris I, Cuevas C, Villa M, Caviedes P, Segura-Aguilar J, Tizabi Y (2012) Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease. Neurotox Res 22(2):177-180
33. Jeyarasasingam G, Tompkins L, Quik M (2002) Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience 109(2):275-285 (Pubitemid 34098968)
34. Mishra NC, Rir-sima-ah J, Boyd RT, Singh SP, Gundavarapu S, Langley RJ, Razani-Boroujerdi S, Sopori ML (2010) Nicotine inhibits Fc epsilon RI-induced cysteinyl leukotrienes and cytokine production without affecting mast cell degranulation through alpha 7/alpha 9/alpha 10-nicotinic receptors. J Immunol 185(1):588-596
35. Quik M, Perez XA, Bordia T (2012) Nicotine as a potential neuroprotective agent for Parkinson's disease. Mov Disord 27(8):947-957
36. Gegg ME, Beltran B, Salas-Pino S, Bolanos JP, Clark JB, Moncada S, Heales SJ (2003) Differential effect of nitric oxide on glutathione metabolism and mitochondrial function in astrocytes and neurones: implications for neuroprotection/neurodegeneration? J Neurochem 86(1):228-237 (Pubitemid 36753863)
37. Rathinam ML, Watts LT, Narasimhan M, Riar AK, Mahimainathan L, Henderson GI (2012) Astrocyte mediated protection of fetal cerebral cortical neurons from rotenone and paraquat. Environ Toxicol Pharmacol 33(2):353-360
38. Bilska A, Dubiel M, Sokołowska-Jezewicz M, Lorenc-Koci E, Włodek L (2007) Alpha-lipoic acid differently affects the reserpine-induced oxidative stress in the striatum and prefrontal cortex of rat brain. Neuroscience 146(4):1758-1771 (Pubitemid 46783235)
39. Harish G, Mahadevan A, Srinivas Bharath MM, Shankar SK (2013) Alteration in glutathione content and associated enzyme activities in the synaptic terminals but not in the non-synaptic mitochondria from the frontal cortex of Parkinson's disease brains. Neurochem Res 38(1):186-200
40. Zeevalk GD, Razmpour R, Bernard LP (2008) Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 62(4):236-249 (Pubitemid 351626446)
41. More SS, Vince R (2012) Potential of a γ-glutamyl-transpeptidase- stable glutathione analogue against amyloid-β toxicity. ACS Chem Neurosci 3(3):204-210
42. Nafia I, Re DB, Masmejean F, Melon C, Kachidian P, Kerkerian-Le Goff L, Nieoullon A, Had-Aissouni L (2008) Preferential vulnerability of mesencephalic dopamine neurons to glutamate transporter dysfunction. J Neurochem 105(2):484-496 (Pubitemid 351490014)
43. Chinta SJ, Kumar JM, Zhang H, Forman HJ, Andersen JK (2006) Up-regulation of gamma-glutamyl transpeptidase activity following glutathione depletion has a compensatory rather than an inhibitory effect on mitochondrial complex I activity: implications for Parkinson's disease. Free Radic Biol Med 40(9):1557-1563
44. Lee A, Anderson AR, Rayfield AJ, Stevens MG, Poronnik P, Meabon JS, Cook DG, Pow DV (2012) Localisation of novel forms of glutamate transporters and the cystine-glutamate antiporter in the choroid plexus: implications for CSF glutamate homeostasis. J Chem Neuroanat 43(1):64-75
45. Jackman NA, Uliasz TF, Hewett JA, Hewett SJ (2010) Regulation of system x(c) (-) activity and expression in astrocytes by interleukin-1β: implications for hypoxic neuronal injury. Glia 58(15):1806-1815
46. Crockett S, Clarke M, Reeves S, Sims B (2011) Cystine glutamate exchanger upregulation by retinoic acid induces neuroprotection in neural stem cells. Neuroreport 22(12):598-602
47. Mattox ML, D'Angelo JA, Grimes ZM, Fiebiger E, Dickinson BL (2012) The cystine/glutamate antiporter regulates indoleamine 2,3-dioxygenase protein levels and enzymatic activity in human dendritic cells. Am J Clin Exp Immunol 1(2):113-123
48. Tavano F, di Mola FF, Latiano A, Palmieri O, Bossa F, Valvano MR, Latiano T, Annese V, Andriulli A, di Sebastiano P (2012) Neuroimmune interactions in patients with inflammatory bowel diseases: disease activity and clinical behavior based on substance P serum levels. J Crohns Colitis 6:563-570
49. Thornton E, Vink R (2012) Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease. PLoS One 7(4):e34138
50. Chu JM, Chen LW, Chan YS, Yung KK (2011) Neuroprotective effects of neurokinin receptor one in dopaminergic neurons are mediated through Akt/PKB cell signaling pathway. Neuropharmacology 61(8):1389-1398
51. Kulka M, Sheen CH, Tancowny BP, Grammer LC, Schleimer RP (2007) Neuropeptides activate human mast cell degranulation and chemokine production. Immunology 123:398-410
52. Block ML, Li G, Qin L, Wu X, Pei Z, Wang T, Wilson B, Yang J, Hong JS (2006) Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 20(2):251-258 (Pubitemid 44933172)
53. Levesque M, Wallman MJ, Parent R, Sik A, Parent A (2007) Neurokinin-1 and neurokinin-3 receptors in primate substantia nigra. Neurosci Res 57:362-371
54. Reid MS, Herrera-Marschitz M, Hokfelt T, Lindefors N, Persson H, Ungerstedt U (1990) Striatonigral GABA, dynorphin, substance P and neurokinin A modulation of nigrostriatal dopamine release: evidence for direct regulatory mechanisms. Exp Brain Res 82:293-303 (Pubitemid 20378088)
55. Anderson G, Beischlag TV, Vinciguerra M, Mazzoccoli G (2013) The circadian clock circuitry and the AHR signaling pathway in physiology and pathology. Biochem Pharmacol 85:1405-1416
56. Akahoshi E, Yoshimura S, Uruno S, Ishihara-Sugano M (2009) Effect of dioxins on regulation of tyrosine hydroxylase gene expression by aryl hydrocarbon receptor: a neurotoxicology study. Environ Health 8:24
57. Maaetoft-Udsen K, Shimoda LM, Frøkiær H, Turner H (2012) Aryl hydrocarbon receptor ligand effects in RBL2H3 cells. J Immunotoxicol 9(3):327-337
58. Filbrandt CR, Wu Z, Zlokovic B, Opanashuk L, Gasiewicz TA (2004) Presence and functional activity of the aryl hydrocarbon receptor in isolated murine cerebral vascular endothelial cells and astrocytes. Neurotoxicology 25(4):605-616 (Pubitemid 38739117)
59. Tsuji G, Takahara M, Uchi H, Matsuda T, Chiba T, Takeuchi S, Yasukawa F, Moroi Y, Furue M (2012) Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes: the basis of its anti-inflammatory effect. J Invest Dermatol 132(1):59-68
60. Rico de Souza A, Zago M, Pollock SJ, Sime PJ, Phipps RP, Baglole CJ (2011) Genetic ablation of the aryl hydrocarbon receptor causes cigarette smoke-induced mitochondrial dysfunction and apoptosis. J Biol Chem 286(50):43214-43228
61. Kim SS, Moon KR, Choi HJ (2011) Interference of alpha-synuclein with cAMP/PKA-dependent CREB signaling for tyrosine hydroxylase gene expression in SK-N-BE(2)C cells. Arch Pharm Res 34(5):837-845
62. Oesch-Bartlomowicz B, Oesch F (2009) Role of cAMP in mediating AHR signaling. Biochem Pharmacol 77:627-641
63. O'Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH (2008) cAMP-dependent signaling as a core component of the mammalian circadian pacemaker. Science 320:949-953 (Pubitemid 351929593)
64. Beaule C, Swanstrom A, Leone MJ, Herzog ED (2009) Circadian modulation of gene expression, but not glutamate uptake, in mouse and rat cortical astrocytes. PLoS ONE 4:e7476
65. Cai Y, Liu S, Sothern RB, Xu S, Chan P (2010) Expression of clock genes Per1 and Bmal1 in total leukocytes in health and Parkinson's disease. Eur J Neurol 17(4):550-554
66. Hayashi A, Matsunaga N, Okazaki H, Kakimoto K, Kimura Y, Azuma H, Ikeda E, Shiba T, Yamato M, Yamada KI, Koyanagi S, Ohdo S (2013) A disruption mechanism of the molecular clock in a MPTP mouse model of Parkinson's disease. Neuromolecular Med 15(2):238-251
67. Kudo T, Loh DH, Truong D, Wu Y, Colwell CS (2011) Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol 232(1):66-75
68. Hua P, Liu W, Kuo SH, Zhao Y, Chen L, Zhang N, Wang C, Guo S, Wang L, Xiao H, Kwan JY, Wu T (2012) Association of Tef polymorphism with depression in Parkinson disease. Mov Disord 27(13):1694-1697
69. Lin Q, Ding H, Zheng Z, Gu Z, Ma J, Chen L, Chan P, Cai Y (2012) Promoter methylation analysis of seven clock genes in Parkinson's disease. Neurosci Lett 507(2):147-150
70. Hood S, Cassidy P, Cossette MP, Weigl Y, Verwey M, Robinson B, Stewart J, Amir S (2010) Endogenous dopamine regulates the rhythm of expression of the clock protein PER2 in the rat dorsal striatum via daily activation of D2 dopamine receptors. J Neurosci 30(42):14046-14058
71. Ye Q, Ye L, Xu X, Huang B, Zhang X, Zhu Y, Chen X (2012) Epigallocatechin-3-gallate suppresses 1-methyl-4-phenyl-pyridine-induced oxidative stress in PC12 cells via the SIRT1/PGC-1α signaling pathway. BMC Complement Altern Med 12:82
72. Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1-3):414-418
73. Wang JF, Shao L, Sun X, Young LT (2009) Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. Bipolar Disord 11(5):523-529
74. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93:2696-2701 (Pubitemid 26114311)
75. Picklo MJ, Amarnath V, McIntyre JO, Graham DG, Montine TJ (1999) 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites. J Neurochem 72:1617-1624 (Pubitemid 29140836)
76. Shin Y, White BH, Uh M, Sidhu A (2003) Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation. Brain Res 968(1):102-113 (Pubitemid 36315680)
77. Jinsmaa Y, Florang VR, Rees JN, Anderson DG, Strack S, Doorn JA (2009) Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate. Chem Res Toxicol 22(5):835-841
78. Chen J, Wang X, Yi X, Wang Y, Liu Q, Ge R (2013) Induction of KLF4 contributes to the neurotoxicity of MPP+ in M17 cells: a new implication in Parkinson's disease. J Mol Neurosci 51(1):109-117
79. Fritz KS, Galligan JJ, Smathers RL, Roede JR, Shearn CT, Reigan P, Petersen DR (2011) 4-Hydroxynonenal inhibits SIRT3 via thiol-specific modification. Chem Res Toxicol 24(5):651-662
80. Kong X, Wang R, Xue Y, Liu X, Zhang H, Chen Y, Fang F, Chang Y (2010) Sirtuin 3, a new target of PGC-1alpha, plays an important role in the suppression of ROS and mitochondrial biogenesis. PLoS One 5(7):e11707
81. Anderson G, Maes M (2013) Oxidative/nitrosative stress and immuno-inflammatory pathways in depression: treatment implications. Curr Pharm Design (in press)
82. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J (2011) Depression's multiple comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways. Neuroendocrinol Lett 32(1):7-24
83. Massudi H, Grant R, Braidy N, Guest J, Farnsworth B, Guillemin GJ (2012) Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One 7(7):e42357
84. Sheline CT, Zhu J, Zhang W, Shi C, Cai AL (2013) Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo. Neurodegener Dis 11(1):49-58
85. Hasegawa K, Wakino S, Yoshioka K, Tatematsu S, Hara Y, Minakuchi H, Washida N, Tokuyama H, Hayashi K, Itoh H (2008) Sirt1 protects against oxidative stress-induced renal tubular cell apoptosis by the bidirectional regulation of catalase expression. Biochem Biophys Res Commun 372:51-56
86. Tanno M, Kuno A, Yano T, Miura T, Hisahara S, Ishikawa S, Shimamoto K, Horio Y (2010) Induction of manganese superoxide dismutase by nuclear translocation and activation of SIRT1 promotes cell survival in chronic heart failure. J Biol Chem 285:8375-8382
87. Kume S, Haneda M, Kanasaki K, Sugimoto T, Araki S, Isono M, Isshiki K, Uzu T, Kashiwagi A, Koya D (2006) Silent information regulator 2 (SIRT1) attenuates oxidative stress-induced mesangial cell apoptosis via p53 deacetylation. Free Radic Biol Med 40:2175-2182 (Pubitemid 43903102)
88. Donmez G, Arun A, Chung CY, McLean PJ, Lindquist S, Guarente L (2012) SIRT1 protects against α-synuclein aggregation by activating molecular chaperones. J Neurosci 32(1):124-132
89. Zhang A, Wang H, Qin X, Pang S, Yan B (2012) Genetic analysis of SIRT1 gene promoter in sporadic Parkinson's disease. Biochem Biophys Res Commun 422(4):693-696
90. Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, Grünblatt E, Moran LB, Mandel SA, Riederer P, Miller RM, Federoff HJ, Wüllner U, Papapetropoulos S, Youdim MB, Cantuti-Castelvetri I, Young AB, Vance JM, Davis RL, Hedreen JC, Adler CH, Beach TG, Graeber MB, Middleton FA, Rochet JC, Scherzer CR, Global PD Gene Expression (GPEX) Consortium (2010) PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med 2(52):52ra73
91. Clark J, Silvaggi JM, Kiselak T, Zheng K, Clore EL, Dai Y, Bass CE, Simon DK (2012) Pgc-1α overexpression downregulates Pitx3 and increases susceptibility to MPTP toxicity associated with decreased Bdnf. PLoS One 7(11):e48925
92. Mudò G, Mäkelä J, Di Liberto V, Tselykh TV, Olivieri M, Piepponen P, Eriksson O, Mälkiä A, Bonomo A, Kairisalo M, Aguirre JA, Korhonen L, Belluardo N, Lindholm D (2012) Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell Mol Life Sci 69(7):1153-1165
93. Clark J, Reddy S, Zheng K, Betensky RA, Simon DK (2011) Association of PGC-1alpha polymorphisms with age of onset and risk of Parkinson's disease. BMC Med Genet 12:69
94. Shin JH, Ko HS, Kang H, Lee Y, Lee YI, Pletinkova O, Troconso JC, Dawson VL, Dawson TM (2011) PARIS (ZNF746) repression of PGC-1α contributes to neurodegeneration in Parkinson's disease. Cell 144(5):689-702
95. Pacelli C, De Rasmo D, Signorile A, Grattagliano I, di Tullio G, D'Orazio A, Nico B, Comi GP, Ronchi D, Ferranini E, Pirolo D, Seibel P, Schubert S, Gaballo A, Villani G, Cocco T (2011) Mitochondrial defect and PGC-1α dysfunction in parkin-associated familial Parkinson's disease. Biochim Biophys Acta 1812(8):1041-1053
96. Braidy N, Guillemin GJ, Grant R (2011) Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons. Int J Tryptophan Res 4:29-37
97. Suh HS, Zhao ML, Rivieccio M, Choi S, Connolly E, Zhao Y, Takikawa O, Brosnan CF, Lee SC (2007) Astrocyte indoleamine 2,3-dioxygenase is induced by the TLR3 ligand poly(I:C): mechanism of induction and role in antiviral response. J Virol 81(18):9838-9850 (Pubitemid 350067687)
98. Weir HJ, Murray TK, Kehoe PG, Love S, Verdin EM, O'Neill MJ, Lane JD, Balthasar N (2012) CNS SIRT3 expression is altered by reactive oxygen species and in Alzheimer's disease. PLoS One 7(11):e48225
99. Weller C, Oxlade N, Dobbs SM, Dobbs RJ, Charlett A, Bjarnason IT (2005) Role of inflammation in gastrointestinal tract in aetiology and pathogenesis of idiopathic parkinsonism. FEMS Immunol Med Microbiol 44(2):129-135 (Pubitemid 41378983)
100. Moylan S, Maes M, Wray NR, Berk M (2013) The neuroprogressive nature of major depressive disorder: pathways to disease evolution and resistance, and therapeutic implications. Mol Psychiatry 18(5):595-606
101. Glorioso C, Oh S, Douillard GG, Sibille E (2011) Brain molecular aging, promotion of neurological disease and modulation by sirtuin 5 longevity gene polymorphism. Neurobiol Dis 41(2):279-290
102. Venkateshappa C, Harish G, Mythri RB, Mahadevan A, Bharath MM, Shankar SK (2012) Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: implications for Parkinson's disease. Neurochem Res 37(2):358-369
103. Watfa G, Dragonas C, Brosche T, Dittrich R, Sieber CC, Alecu C, Benetos A, Nzietchueng R (2011) Study of telomere length and different markers of oxidative stress in patients with Parkinson's disease. J Nutr Health Aging 15(4):277-281
104. Maeda T, Guan JZ, Koyanagi M, Higuchi Y, Makino N (2012) Aging-associated alteration of telomere length and subtelomeric status in female patients with Parkinson's disease. J Neurogenet 26(2):245-251
105. Hudson G, Faini D, Stutt A, Eccles M, Robinson L, Burn DJ, Chinnery PF (2011) No evidence of substantia nigra telomere shortening in Parkinson's disease. Neurobiol Aging 32(11):2107.e3-5
106. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, Nierenberg AA, Fava M, Wong KK (2006) Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry 60(5):432-435 (Pubitemid 44292160)
107. Liu L, Arun A, Ellis L, Peritore C, Donmez G (2012) Sirtuin 2 (SIRT2) enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced nigrostriatal damage via deacetylating forkhead box O3a (Foxo3a) and activating Bim protein. J Biol Chem 287(39):32307-32311
108. Hasegawa T, Baba T, Kobayashi M, Konno M, Sugeno N, Kikuchi A, Itoyama Y, Takeda A (2010) Role of TPPP/p25 on α-synuclein-mediated oligodendroglial degeneration and the protective effect of SIRT2 inhibition in a cellular model of multiple system atrophy. Neurochem Int 57(8):857-866
109. Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, Quinti L, Chopra V, Hersch SM, Kazantsev AG (2011) The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet 20(20):3986-3996
110. Leonard S, Luthman D, Logel J, Luthman J, Antle C, Freedman R, Hoffer B (1993) Acidic and basic fibroblast growth factor mRNAs are increased in striatum following MPTP-induced dopamine neurofiber lesion: assay by quantitative PCR. Brain Res Mol Brain Res 18(4):275-284
111. Brough D, Pelegrin P, Rothwell NJ (2009) Pannexin-1-dependent caspase-1 activation and secretion of IL-1b is regulated by zinc. Eur J Immunol 39:352-358
112. Silverman WR, de Rivero Vaccari JP, Locovei S, Qiu F, Carlsson SK, Scemes E, Keane RW, Dahl G (2009) The pannexin 1 channel activates the inflammasome in neurons and astrocytes. J Biol Chem 284(27):18143-18151
113. Ito J-I, Nagayasu Y, Lu R, Kheirollah A, Hayashi M, Yokoyama S (2005) Astrocytes produce and secrete FGF-1, which promotes the production of apoE-HDL in a manner of autocrine action. J Lipid Res 46:679-686 (Pubitemid 43073277)
114. Kacer D, McIntire C, Kirov A, Kany E, Roth J, Liaw L, Small D, Friesel R, Basilico C, Tarantini F, Verdi J, Prudovsky I (2011) Regulation of non-classical FGF1 release and FGF-dependent cell transformation by CBF1-mediated notch signaling. J Cell Physiol 226(11):3064-3075
115. Dai YB, Tan XJ, Wu WF, Warner M, Gustafsson JÅ (2012) Liver X receptor β protects dopaminergic neurons in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A 109(32):13112-13117
116. Cheng X, Wang Z, Yang J, Ma M, Lu T, Xu G, Liu X (2011) Acidic fibroblast growth factor delivered intranasally induces neurogenesis and angiogenesis in rats after ischemic stroke. Neurol Res 33(7):675-680
117. Harada J, Foley M, Moskowitz MA, Waeber C (2004) Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J Neurochem 88(4):1026-1039 (Pubitemid 38199325)
118. Bassi R, Anelli V, Giussani P, Tettamanti G, Viani P, Riboni L (2006) Sphingosine-1-phosphate is released by cerebellar astrocytes in response to bFGF and induces astrocyte proliferation through Gi-protein-coupled receptors. Glia 53(6):621-630
119. Sacchetti P, Sousa KM, Hall AC, Liste I, Steffensen KR, Theofilopoulos S, Parish CL, Hazenberg C, Richter LA, Hovatta O, Gustafsson JA, Arenas E (2009) Liver X receptors and oxysterols promote ventral midbrain neurogenesis in vivo and in human embryonic stem cells. Cell Stem Cell 5(4):409-419
120. Di Serio C, Cozzi A, Angeli I, Doria L, Micucci I, Pellerito S, Mirone P, Masotti G, Moroni F, Tarantini F (2005) Kynurenic acid inhibits the release of the neurotrophic fibroblast growth factor (FGF)-1 and enhances proliferation of glia cells, in vitro. Cell Mol Neurobiol 25(6):981-993 (Pubitemid 43154822)
121. Domenger D, Dea D, Theroux L, Moquin L, Gratton A, Poirier J (2012) The MPTP neurotoxic lesion model of Parkinson's disease activates the apolipoprotein E cascade in the mouse brain. Exp Neurol 233(1):513-522
122. Xia J, Lim JC, Lu W, Beckel JM, Macarak EJ, Laties AM, Mitchell CH (2012) Neurons respond directly to mechanical deformation with pannexin-mediated ATP release and autostimulation of P2X7 receptors. J Physiol 590(Pt 10):2285-2304
123. Garré JM, Retamal MA, Cassina P, Barbeito L, Bukauskas FF, Sáez JC, Bennett MVL, Abudara V (2010) FGF-1 induces ATP release from spinal astrocytes in culture and opens pannexin and connexin hemichannels. PNAS 107(52):22659-22664
124. Xu X, Li D, He Q, Gao J, Chen B, Xie A (2011) Interleukin-18 promoter polymorphisms and risk of Parkinson's disease in a Han Chinese population. Brain Res 1381:90-94
125. Pascale E, Passarelli E, Purcaro C, Vestri AR, Fakeri A, Guglielmi R, Passarelli F, Meco G (2011) Lack of association between IL-1β, TNF-α, and IL-10 gene polymorphisms and sporadic Parkinson's disease in an Italian cohort. Acta Neurol Scand 124(3):176-181
126. Prossin AR, Koch AE, Campbell PL, McInnis MG, Zalcman SS, Zubieta JK (2011) Association of plasma interleukin-18 levels with emotion regulation and μ-opioid neurotransmitter function in major depression and healthy volunteers. Biol Psychiatry 69(8):808-812
127. Lee M, Kang Y, Suk K, Schwab C, Yu S, McGeer PL (2011) Acidic fibroblast growth factor (FGF) potentiates glial-mediated neurotoxicity by activating FGFR2 IIIb protein. J Biol Chem 286(48):41230-41245
128. Adeosun SO, Hou X, Jiao Y, Zheng B, Henry S, Hill R, He Z, Pani A, Kyle P, Ou X, Mosley T, Farley JM, Stockmeier C, Paul I, Bigler S, Brinton RD, Smeyne R, Wang JM (2012) Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease. PLoS One 7(11):e50040
129. Muxel SM, Pires-Lapa MA, Monteiro AWA, Cecon E, Tamura EK, Floeter-Winter LM, Markus RP (2012) NF-kB drives the synthesis of melatonin in RAW 264.7 macrophages by inducing the transcription of the arylalkylamine-N- acetyltransferase (AA-NAT) gene. PLoS ONE 7(12):e52010
130. Fernandes PA, Cecon E, Markus RP, Ferreira ZS (2006) Effect of TNF-alpha on the melatonin synthetic pathway in the rat pineal gland: basis for a 'feedback' of the immune response on circadian timing. J Pineal Res 41:344-350 (Pubitemid 44498220)
131. Liu YJ, Zhuang J, Zhu HY, Shen YX, Tan ZL, Zhou JN (2007) Cultured rat cortical astrocytes synthesize melatonin: absence of a diurnal rhythm. J Pineal Res 43(3):232-238 (Pubitemid 47353000)
132. Pontes GN, Cardoso EC, Carneiro-Sampaio MM, Markus RP (2007) Pineal melatonin and the innate immune response: the TNF-alpha increase after cesarean section suppress nocturnal melatonin production. J Pineal Res 43:365-371 (Pubitemid 47512268)
133. Liu YJ, Meng FT, Wang LL, Zhang LF, Cheng XP, Zhou JN (2012) Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells. J Pineal Res 52(4):397-402
134. Jang SW, Liu X, Pradoldeja S, Tosini G, Chang Q, Iuvone PM, Ye K (2010) N-acetylserotonin activates TrkB receptor in a circadian rhythm. Proc Natl Acad Sci 107(8):3876-3881
135. Castagnoli K, Petzer JB, Steyn SJ, van der Schyf CJ, Castagnoli N Jr (2003) Inhibition of human MAO-A and MAO-B by a compound isolated from flue-cured tobacco leaves and its neuroprotective properties in the MPTP mouse model of neurodegeneration. Inflammopharmacology 11:183-188 (Pubitemid 36807337)
136. Hoglinger GU, Rizk P, Muriel MP, Duyckaerts C, Oertel WH, Caille I, Hirsch EC (2004) Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat Neurosci 7:726-735 (Pubitemid 38859057)
137. Crews L, Mizuno H, Desplats P, Rockenstein E, Adame A, Patrick C, Winner B, Winkler J, Masliah E (2008) Alpha-synuclein alters Notch-1 expression and neurogenesis in mouse embryonic stem cells and in the hippocampus of transgenic mice. J Neurosci 28:4250-4260
138. Desplats P, Spencer B, Crews L, Pathel P, Morvinski-Friedmann D, Kosberg K, Roberts S, Patrick C, Winner B, Winkler J, Masliah E (2012) α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. J Biol Chem 287(38):31691-31702
139. Winner B, Rockenstein E, Lie DC, Aigner R, Mante M, Bogdahn U, Couillard-Despres S, Masliah E, Winkler J (2008) Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol Aging 29(6):913-925 (Pubitemid 351601896)
140. May VE, Nuber S, Marxreiter F, Riess O, Winner B, Winkler J (2012) Impaired olfactory bulb neurogenesis depends on the presence of human wild-type alpha-synuclein. Neuroscience 222:343-355
141. Enciu AM, Nicolescu MI, Manole CG, Muresanu DF, Popescu LM, Popescu BO (2011) Neuroregeneration in neurodegenerative disorders. BMC Neurol 11:75
142. Marxreiter F, Regensburger M, Winkler J (2013) Adult neurogenesis in Parkinson's disease. Cell Mol Life Sci 70(3):459-473
143. Kanai M, Funakoshi H, Takahashi H, Hayakawa T, Mizuno S, Matsumoto K, Nakamura T (2009) Tryptophan 2,3-dioxygenase is a key modulator of physiological neurogenesis and anxiety-related behavior in mice. Mol Brain 2:8
144. Nautiyal KM, Dailey CA, Jahn JL, Rodriquez E, Son NH, Sweedler JV, Silver R (2012) Serotonin of mast cell origin contributes to hippocampal function. Eur J Neurosci 36(3):2347-2359
145. Tiberi L, van den Ameele J, Dimidschstein J, Piccirilli J, Gall D, Herpoel A, Bilheu A, Bonnefont J, Iacovino M, Kyba M, Bouschet T, Vanderhaeghen P (2012) BCL6 controls neurogenesis through Sirt1-dependent epigenetic repression of selective Notch targets. Nat Neurosci 15(12):1627-1635
146. Libert S, Cohen D, Guarente L (2008) Neurogenesis directed by Sirt1. Nat Cell Biol 10(4):373-374
147. Luo CX, Jin X, Cao CC, Zhu MM, Wang B, Chang L, Zhou QG, Wu HY, Zhu DY (2010) Bidirectional regulation of neurogenesis by neuronal nitric oxide synthase derived fromneurons and neural stem cells. Stem Cells 28(11):2041-2052